These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 7508147)

  • 1. [Antiestrogens (tamoxifen) in the alternative therapy of benign prostatic hyperplasia].
    Hanus M; Matousková M
    Rozhl Chir; 1993 Oct; 72(7):316-8. PubMed ID: 7508147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Alternative therapy of benign prostatic hypertrophy--Permixon (Capistan)].
    Hanus M; Matousková M
    Rozhl Chir; 1993 Feb; 72(2):75-9. PubMed ID: 7692609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An experimental study of the inhibition of tamoxifen on rat model of benign prostatic hyperplasia].
    Chen B; Bai JL; Zhang SS; Fu W
    Zhonghua Nan Ke Xue; 2002; 8(2):98-102. PubMed ID: 12479019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial.
    Pande S; Hazra A; Kundu AK
    Indian J Pharmacol; 2014; 46(6):601-7. PubMed ID: 25538330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Echotomographic evaluation of the recent endocrine trends in the treatment of so-called prostatic hypertrophy].
    Napolitano A; Gargano E; Criniti P; Zezza A; Seccia M; Galfano G
    Ann Ital Chir; 1983; 55(2):161-7. PubMed ID: 6197917
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Roehrborn CG; Chapple C; Oelke M; Cox D; Esler A; Viktrup L
    J Urol; 2014 Apr; 191(4):1045-50. PubMed ID: 24445278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
    Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
    Wang YY; Shi GW; He JY; Zhang YB
    Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1099-102. PubMed ID: 24432622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial.
    Sengupta G; Hazra A; Kundu A; Ghosh A
    Clin Ther; 2011 Dec; 33(12):1943-52. PubMed ID: 22177370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2009 Dec; 182(6):2831-5. PubMed ID: 19837428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2014 Sep; 114(3):427-33. PubMed ID: 24571313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effect of the aromatase inhibitor, anastrazole, to the antioestrogen, tamoxifen citrate, on canine prostate and semen.
    Gonzalez G; Guendulain C; Maffrand C; Gobello C
    Reprod Domest Anim; 2009 Jul; 44 Suppl 2():316-9. PubMed ID: 19754594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
    Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
    Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study.
    Choo MS; Song M; Kim JH; Lee KS; Kim JC; Kim SW; Yang SK; Lee JG; Lee JZ; Kim DK; Park WH; Kim KD; Na YG; Kwon DD; Paick JS
    Urology; 2014 Apr; 83(4):875-81. PubMed ID: 24529580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tamoxifen citrate on reproductive parameters of male dogs.
    Corrada Y; Arias D; Rodríguez R; Spaini E; Fava F; Gobello C
    Theriogenology; 2004 May; 61(7-8):1327-41. PubMed ID: 15036966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
    N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.